The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
10 reports and counting
CatalystLaunch Software raises $153M Series D at $464M valuation
CatalystLaunch Software secures $153M in Series D funding led by DST Global, reaching $464M valuation as it accelerates growth in the supply chain sector.
AccelerateStack Networks raises $36M Series B at $153M valuation
AccelerateStack Networks secures $36M in Series B funding led by Coatue, reaching $153M valuation as it accelerates growth in the media sector.
AccelerateCore Software raises $42M Series C at $153M valuation
AccelerateCore Software secures $42M in Series C funding led by Index Ventures, reaching $153M valuation as it accelerates growth in the ai/ml sector.
Upstream Bio Raises $153M in Series B
Upstream Bio, a Biotech company based in Waltham, MA, has raised $153M in Series B at a $800M valuation led by Fidelity, Viking Global.
Strand Therapeutics Raises $153M in Series B
Strand Therapeutics, a HealthTech company based in Cambridge, MA, has raised $153M in Series B led by Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures.
Arthrosi Therapeutics Raises $153M in Series E
Arthrosi Therapeutics, a Biotech company based in San Diego, CA, has raised $153M in Series E at a $800M valuation led by New Enterprise Associates, RA Capital.
Strand Therapeutics Raises $153M Series B to Transform Biotech
Strand Therapeutics has secured $153M Series B in funding to accelerate growth and innovation in the biotech sector. Synthetic biology company programming mRNA therapies with logic-gated controls for precision oncology treatments...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Upstream Bio raises $153M Series B at $800M valuation
Upstream Bio raises $153M in Series B at $800M valuation. Developing antibody therapeutics for inflammatory diseases...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.